Nonpeptide Antagonists of AT1 Receptor for Angiotensin II Delay the Onset of Acute Respiratory Distress Syndrome

• Published in: The Journal of pharmacology and experimental therapeutics Vol. 303; no. 1; pp. 45 - 51
• Main Authors: Raiden, Silvina, Nahmod, Karen, Nahmod, Víctor, Semeniuk, Guillermo, Pereira, Yanina, Alvarez, Clarisa, Giordano, Mirta, Geffner, Jorge R
• Format: Journal Article
• Language: English
• Published: United States American Society for Pharmacology and Experimental Therapeutics 01.10.2002
• Subjects: Angiotensin II - metabolism; Angiotensin Receptor Antagonists; Animals; Bordetella bronchiseptica; Bordetella Infections - pathology; Bordetella Infections - physiopathology; Calcium - blood; Kinetics; Losartan - pharmacology; Lung - pathology; Male; Neutrophils - physiology; Oxygen - blood; Peroxidase - blood; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Renin-Angiotensin System - drug effects; Respiratory Distress Syndrome, Adult - pathology; Respiratory Distress Syndrome, Adult - physiopathology; Respiratory Distress Syndrome, Adult - prevention & control
• ISSN: 0022-3565; 1521-0103
• DOI: 10.1124/jpet.102.037382

We have previously reported that losartan, a selective antagonist of AT1 receptors for angiotensin II (AII), strongly suppresses the activation of neutrophils by N -formylmethionyl-leucyl-phenylalanine (fMLP) through a mechanism that does not involve inhibition of AT1 receptors. Herein, we analyze whether losartan would prevent the development of the acute respiratory distress syndrome (ARDS) triggered by lung bacterial infection. We found that losartan (0.2–200 μg/kg/min) delays the onset of ARDS in Wistar rats challenged by i.t. instillation of Bordetella bronchiseptica . Although this effect was associated with a significant inhibition of lung-neutrophil recruitment, lung bacterial clearance was not impaired but rather, it was significantly improved. We also found that another nonpeptide AT1 receptor blocker, irbesartan, exerted similar effects to losartan, i.e., it was also able to inhibit neutrophil activation by fMLP and to delay the onset of ARDS in B. bronchiseptica- challenged rats. Neither the inhibitor of angiotensin-converting enzyme captopril, nor the nonselective peptide inhibitor of AII receptors saralasin reproduced these effects. Our data are consistent with the possibility that nonpeptide AT1 receptor blockers delay the onset of ARDS triggered by bacterial infection through a mechanism dependent, at least in part, on their ability to prevent neutrophil activation by N -formyl-peptides.